In light of the LUAD current biomarker situation, it will be valuable to establish a proper model and explore the potential of Prx4 as a high-utility, non-invasive tool for early diagnosis and dependable patient monitoring in lung cancer patients. Here, PRDX4 is linked to lung carcinoma.